Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel
NASDAQ:HROW

Harrow Q3 2026 Earnings Date & Estimates

Harrow logo
$27.24 -1.00 (-3.54%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$27.96 +0.72 (+2.63%)
As of 10/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Harrow is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for November 10, 2026 at 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Harrow in Q3 2026

Harrow is expected to post earnings of $0.16 per share on revenue of $98.47 million. In the same quarter a year earlier Harrow reported $0.33 per share on revenue of $71.64 million. Harrow last reported on August 10, 2026, posting -$0.46 per share and missing the -$0.1788 consensus estimate. Harrow has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.16
Expected Revenue
$98.47 million
Prior-Year EPS
$0.33
Prior-Year Revenue
$71.64 million
Expected EPS Growth
-51.5%
Expected Revenue Growth
+37.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.46 (Missed by -$0.2813)
Last Quarter Revenue
$70.66 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Harrow Q3 2026 Earnings FAQ

Harrow (NASDAQ:HROW) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Harrow's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Harrow to post earnings of $0.16 per share for Q3 2026.

The consensus revenue estimate for Harrow is $98.47 million for Q3 2026.

Harrow Earnings Headlines

Lake Street Keeps Their Buy Rating on Harrow Health (HROW)
October 14 at 9:19 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HROW/pressreleases/4984072/lake-street-keeps-their-buy-rating-on-harrow-health-hrow/
Do Options Traders Know Something About Harrow Stock We Don't?
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/options/articles/options-traders-know-something-harrow-114600398.html
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
 |  The Oxford Club (Ad)
Harrow: Q3 Needs To Prove The Turnaround Is Real
October 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952759-harrow-q3-needs-to-prove-the-turnaround-is-real
Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/harrow-hrow-undervalued-growing-conference-011540673.html
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098100
See More Harrow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email.

About Harrow

Harrow (NASDAQ:HROW) is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing prescription products for the treatment of eye conditions. Its portfolio is designed to serve ophthalmologists, optometrists, ambulatory surgery centers, and other eye-care providers across areas including dry eye disease, ocular inflammation, infection, and surgical care.

The company’s products include VEVYE, a cyclosporine ophthalmic emulsion for the treatment of signs and symptoms of dry eye disease, and IHEEZO, an ophthalmic anesthetic used in certain ocular procedures. Harrow has also been associated with a broader portfolio of branded ophthalmic medicines and operates through businesses that provide compounded and specialty pharmaceutical products for eye-care professionals and patients.

Founded in 2012, Harrow is headquartered in Nashville, Tennessee, and primarily serves the United States ophthalmology market. The company is led by Mark L. Baum, who serves as its founder and chief executive officer. Its strategy centers on expanding access to ophthalmic therapies through a combination of product development, commercialization, licensing, and specialized pharmacy operations.

View Harrow Profile
Earnings Tools